All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Vicore Pharma Holding AB and its partner Alex Therapeutics AB reported positive results from the U.S. pilot phase of a study assessing the effects of digitally delivered cognitive behavioral therapy (CBT) in treating anxiety in patients with idiopathic pulmonary fibrosis (IPF). The four-week study in 10 patients found the digital therapeutic, called Almee, functioned properly, was safe and the user experience was favorable.
Circuit dysfunction is clearly recognized as a driver of neuropsychiatric disease, and some neurodegenerative diseases such as Parkinson’s disease. And at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 Congress, researchers made an argument that the same is true in multiple sclerosis (MS). Such a lens could explain the radiological-clinical paradox between the amount of structural damage and clinical severity.
The new EU Medical Devices Regulation (MDR) is not going down well with Swiss medical technology manufacturers. At a conference held on Oct. 19 in Bern, Switzerland on introducing the new EU MDR, the Swiss medical technology association, Swiss Medtech, which represents more than 700 firms, put out a harsh and definitive statement.
Medtronic plc has launched Medtronic Neurovascular Co-Lab platform, a major initiative to speed the pace of innovations in stroke treatment and access for patients around the world. The neurovascular innovation incubator will bring together innovators, entrepreneurs and physicians to collaborate and share their ideas about promising products and solutions.
The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.
It’s a time of economic crisis and political upheaval in the U.K. But, according to the country’s pharma trade body, there’s another looming problem of access to clinical trials in the country, which is becoming less and less attractive as a place to conduct life sciences research.
Just days after taking the helm of Royal Philips NV, CEO Roy Jakobs told shareholders that the company plans to “immediately reduce our workforce by around 4,000 roles globally” as a result of multiple challenges that contributed to poorer than expected third quarter results. The company posted a net loss for the quarter, missing consensus, which it attributed to continuing supply chain issues and the deteriorating economic environment.
The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.
The U.K. is launching a coordinated national program of research into the unprecedented outbreak of monkeypox that has spread across Europe and North America – regions where the disease is not endemic – over the past six months. Taking a lead from the SARS-CoV-2 playbook, there will be work to sequence the viral genome and to study how it is evolving, linking this to changes in the transmission and pathology of the virus.
The U.K. is launching a coordinated national program of research into the unprecedented outbreak of monkeypox that has spread across Europe and North America – regions where the disease is not endemic – over the past six months. Taking a lead from the SARS-CoV-2 playbook, there will be work to sequence the viral genome and to study how it is evolving, linking this to changes in the transmission and pathology of the virus.
RSS
